Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAPT ALEC: TDM-guided vs Standard Alectinib in ALK+ NSCLC
NCT05525338Phase 4Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Mar 2022
- Primary completion
- Dec 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial of alectinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by University Medical Center Groningen. Primary endpoint: Median Progression Free Survival. Started Mar 2022; status: recruiting.
02
Drugs
alectinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05525338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05525338.